Drug Watch

Latest News

April in Review: Updates on the Psychiatric Treatment Pipeline

By Leah Kuntz

April 30th 2025

Check out the pipeline updates from April!

First-of-its-Kind Study: Using a Novel Platform to Assess Patients With Borderline Personality Disorder

By Leah Kuntz

April 29th 2025

A groundbreaking study explores innovative neuroassessment technology to enhance understanding and treatment of borderline personality disorder symptoms.

Transneural Therapeutics: A New Company to Develop Novel Neuroplastogens

By Leah Kuntz

April 23rd 2025

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial

By Leah Kuntz

April 22nd 2025

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin Announces Partnership With Osmind to Advance Clinical-Stage Psychiatry Programs

By Leah Kuntz

April 22nd 2025

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

<1 2 3 4 5 6

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777